Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

Date publication

décembre 2015

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr VERNEREY Dewi

Tous les auteurs :
André T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T, Tabernero J, Van Laethem JL, Banzi M, Maartense E, Shmueli E, Carlsson GU, Scheithauer W, Papamichael D, Möehler M, Landolfi S, Demetter P, Colote S, Tournigand C, Louvet C, Duval A, Fléjou JF, de Gramont A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26527776

Résumé

The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer) study has demonstrated 3-year disease-free survival (DFS) and 6-year overall survival (OS) benefit of adjuvant oxaliplatin in stage II to III resected colon cancer. This update presents 10-year OS and OS and DFS by mismatch repair (MMR) status and BRAF mutation.

Mots clés

Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, administration & dosage, Chemotherapy, Adjuvant, Colonic Neoplasms, drug therapy, DNA Mismatch Repair, Disease-Free Survival, Female, Fluorouracil, administration & dosage, Follow-Up Studies, Glutamic Acid, Humans, Infusions, Intravenous, Injections, Intravenous, Kaplan-Meier Estimate, Leucovorin, administration & dosage, Male, Middle Aged, Mutation, Neoplasm Staging, Odds Ratio, Organoplatinum Compounds, administration & dosage, Prognosis, Proto-Oncogene Proteins B-raf, genetics, Treatment Outcome, Valine

Référence

J. Clin. Oncol.. 2015 Dec 10;33(35):4176-87